12:00 AM
 | 
Jan 30, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vertical Auto Profile diagnostic data

Researchers at Thomas Jefferson University reported data from a 2-year retrospective study in 2,056 patients with congestive heart failure (CHF) or ischemic heart disease showing that patients whose treatment protocol incorporated comprehensive lipid profiling with Atherotech's VAP Cholesterol Test had a significant 35% reduction in total treatment costs vs. a control group of patients who received traditional lipid testing or no testing ($4,852.62 vs. $7,413.18, p=0.0255). VAP testing also led to a significantly lower rate of inpatient stays (13.1% vs. 18.3%, p=0.0175) and emergency department visits vs. controls (11.9% vs. 15.6%,...

Read the full 432 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >